Pharma Industry Reputation: What Is At Stake With COVID-19?

The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.

IV2008_Pharma-Reputation_1200.jpg
Industry reputations have much to gain – or lose – from the ongoing response to COVID-19

More from Leadership

More from In Vivo